Huang Z - Search Results

1

Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression.

Peng J, Zhai X, Liu X, Huang Z, Wang Y, Wu P, Gao R, Meng X. Peng J, et al. Among authors: huang z. Transl Oncol. 2024 Dec 21;52:102249. doi: 10.1016/j.tranon.2024.102249. Online ahead of print. Transl Oncol. 2024. PMID: 39709719 Free article.

2

Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer.

Peng J, Zhang L, Wang L, Feng H, Yao D, Meng R, Liu X, Li X, Liu N, Tan B, Huang Z, Li S, Meng X. Peng J, et al. Among authors: huang z. Radiat Oncol. 2023 Jul 4;18(1):111. doi: 10.1186/s13014-023-02308-2. Radiat Oncol. 2023. PMID: 37403111 Free PMC article.

3

Eczema as the first manifestation of a lung cancer.

Meng X, Wang R, Huang Z, Yu J. Meng X, et al. Among authors: huang z. J Cancer Res Ther. 2015 Jul-Sep;11(3):659. doi: 10.4103/0973-1482.144373. J Cancer Res Ther. 2015. PMID: 26458667 Free article.

4

Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.

Meng X, Huang Z, Teng F, Xing L, Yu J. Meng X, et al. Among authors: huang z. Cancer Treat Rev. 2015 Dec;41(10):868-76. doi: 10.1016/j.ctrv.2015.11.001. Epub 2015 Nov 10. Cancer Treat Rev. 2015. PMID: 26589760 Review.

5

Radiation Recall Pneumonitis Induced by Anti-PD-1 Blockade: A Case Report and Review of the Literature.

Chen Y, Huang Z, Xing L, Meng X, Yu J. Chen Y, et al. Among authors: huang z. Front Oncol. 2020 Apr 28;10:561. doi: 10.3389/fonc.2020.00561. eCollection 2020. Front Oncol. 2020. PMID: 32411597 Free PMC article.

6

Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice.

Chen Y, Pei Y, Luo J, Huang Z, Yu J, Meng X. Chen Y, et al. Among authors: huang z. Front Immunol. 2020 May 29;11:1088. doi: 10.3389/fimmu.2020.01088. eCollection 2020. Front Immunol. 2020. PMID: 32547566 Free PMC article. Review.

7

SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.

Chen Y, Gao M, Huang Z, Yu J, Meng X. Chen Y, et al. Among authors: huang z. J Hematol Oncol. 2020 Jul 28;13(1):105. doi: 10.1186/s13045-020-00940-z. J Hematol Oncol. 2020. PMID: 32723363 Free PMC article. Review.

8

Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.

Zhou S, Xie J, Huang Z, Deng L, Wu L, Yu J, Meng X. Zhou S, et al. Among authors: huang z. Cancer Lett. 2021 Apr 1;502:166-179. doi: 10.1016/j.canlet.2020.12.043. Epub 2021 Jan 13. Cancer Lett. 2021. PMID: 33450361

9

Safety of thoracic radiotherapy after PD-(L)1 inhibitor treatment in patients with lung cancer.

Chen Y, Liu X, Huang Z, Zhao K, Wang Y, Ren F, Yu J, Meng X. Chen Y, et al. Among authors: huang z. Cancer Med. 2021 Dec;10(23):8518-8529. doi: 10.1002/cam4.4363. Epub 2021 Oct 19. Cancer Med. 2021. PMID: 34664788 Free PMC article.

10

The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation.

Ma L, Diao B, Huang Z, Wang B, Yu J, Meng X. Ma L, et al. Among authors: huang z. Cancer Commun (Lond). 2021 Dec;41(12):1314-1330. doi: 10.1002/cac2.12229. Epub 2021 Oct 26. Cancer Commun (Lond). 2021. PMID: 34699691 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

31,001 results

Search Page

Filters